ArticleApplied microbiology and biotechnology2026
Establishment and validation of a rat sepsis model aligned with sepsis-3 via Staphylococcus aureus tail vein infection.
Article in Applied microbiology and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sepsis, a life-threatening organ dysfunction stemming from uncontrolled host responses to infection, continues to be a leading global health threat. Despite the establishment of diverse preclinical animal models for sepsis research, their inherent deficiencies have significantly hindered their clinical translation. In this study, we developed a rat model of sepsis through continuous tail vein injection of a single, defined Staphylococcus aureus strain. Bacteriological identification confirmed the exclusive presence of the inoculated pathogen. The model recapitulated key clinical features of human sepsis, including altered mental status, respiration, and fever. Biochemical tests of peripheral blood revealed that the model rats and clinical sepsis patients presented similar alterations in indicators related to coagulation function and the cardiac, hepatic, and renal systems. Compared with the control group, model rats exhibited increased platelet counts (P < 0.05), total bilirubin, urea, and cystatin levels (P < 0.001, P < 0.01, P < 0.05, respectively). Histopathological and ultrastructural examinations confirmed multi-organ damage. Additionally, tandem mass tag proteomics analysis identified a total of 707 significantly differentially expressed proteins (P < 0.05, fold change > 1.2), with 279 upregulated and 428 downregulated in the model group compared to the control group. These proteins were enriched in inflammatory and immune responses, signal transduction, and oxidative stress pathways, systematically revealing molecular-level dysregulation. Collectively, our model meets Sepsis-3 and provides a standardized, stable, and reproducible platform for mechanistic research and therapeutic development. KEY POINTS: A standardized rat sepsis model via sustained Staphylococcus aureus tail vein injection was established. The model meets Sepsis-3 through multilevel clinical and pathological validation. It provides a stable, reproducible tool for mechanistic research and therapeutic development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.